

17th World Congress of the Academy of Human Reproduction

15–18 March 2017
Rome, Italy

TITLE

EVALUATION OF FACTORS THAT CONTRIBUTE TO SATISFACTION WITH TWO TYPES OF COMBINED ORAL CONTRACEPTIVES (COCS)

AUTHOR/S

Mares P (FR) [1], Jamin C (FR) , Gelas B (FR) [2], Micheletti M (NL) [3]

ABSTRACT

Context: Understanding the reasons behind women's satisfaction with COCs might be a means of improving persistence of a COC.

Objective: To assess factors that contribute to COC satisfaction; also, to obtain socio-demographic and other characteristics of COC users.

Methods: Non-comparative, non-interventional, descriptive study conducted in France; data were collected from a 51-question online self-assessment questionnaire.

Patients: Sexually active women, age 18-35 years, on COCs with no prior time limit.

Interventions: Norgestrel acetate 2.5mg and estradiol 1.5mg (NOMAC/E2; Zoely®), or levonorgestrel 100µg and ethinyl estradiol 20µg (LNG/EE; Leeloo Ge®).

Main Outcome Measures: Satisfaction with NOMAC/E2 vs LNG/EE.

Results: A total of 2,065 women were included (NOMAC/E2 n=504; LNG/EE n=1,561). The majority of NOMAC/E2 and LNG/EE users reported being satisfied (86% and 75%, respectively ["satisfied" plus "very satisfied"]). The main reasons for satisfaction for NOMAC/E2 were efficacy (79%), convenience (65%), and acceptable price (47%), and for LNG/EE were absence of adverse events (71%), efficacy (52%), and acceptable price (48%). NOMAC/E2 users were more satisfied with their general wellbeing than LNG/EE users (83% vs 69%, respectively) and they believed that their current pill contributed to their wellbeing (78% vs 24%). NOMAC/E2 users were slightly older on average than LNG/EE users (27 and 25 years, respectively). More NOMAC/E2 users reported having a higher education (71% and 52%, respectively), having a full time job (64% and 41%), being a non-smoker (80% and 65%), being a first-time contraceptive user (88% and 61%), and having never been pregnant (80% and 75%) compared to LNG/EE users.

Conclusions: NOMAC/E2 and LNG/EE users reported satisfaction, driven in large part by factors such as efficacy, convenience, absence of adverse events, and acceptable price.

INSTITUTE

[1] Hôpital Universitaire Caremeau, [2] Teva Pharma Medical Affairs, [3] Teva Europe Women's Health